Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03504956
Other study ID # 45312
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 30, 2018
Est. completion date December 31, 2026

Study information

Verified date March 2024
Source Cedars-Sinai Medical Center
Contact Rhona Littman
Phone 310 423-4387
Email rhona.littman@cshs.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study proposes to develop an MRI technique named Coronary Atherosclerosis T1-weighed Characterization (CATCH) that will improve the quality and reliability of coronary atherosclerosis evaluation, as well as simplify the scanning process and significantly shorten imaging time compared with conventional imaging methods.


Description:

Approximately 100 healthy male/female adult "normals" or "controls" and 40 male/female adult outpatients who are suspected of having or have been diagnosed with coronary artery disease will be recruited. All subjects will be asked to undergo either a non-contrast MRI or a contrast-enhanced MRI of the coronary artery depending upon the focus of development at the time of their participation It is anticipated that healthy volunteers will undergo non-contrast or contrast-enhanced MRI for evaluating the image quality associated with each acquisition module of the developed technique and motion artifact associated with motion compensation strategy. For subjects receiving contrast, a total dose of up to 0.2 mmol/kg of a gadolinium based contrast agent will be injected intravenously provided all the safety requirements are met. Subjects undergoing a contrast-enhanced MRI will be screened using the standard clinical protocol to determine whether it is safe to administer contrast. If subjects do not qualify for contrast administration, they may be asked to have a research scan without contrast. Research MRI results will be compared with clinical diagnostic CT and/or invasive imaging studies for patients who have been evaluated with these exams at Cedars-Sinai Medical Center..


Recruitment information / eligibility

Status Recruiting
Enrollment 140
Est. completion date December 31, 2026
Est. primary completion date December 31, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion: - Healthy Volunteers: male or female = 18 years of age with a BMI<30, with no history of cardiovascular disease - Patients: Medically stable, male or female = 18 years of age who is have not suspected of having or has been diagnosed with coronary artery disease and undergone stenting or bypass surgery Exclusion: - Contraindications to MR imaging including mechanically, magnetically, or electrically activated implants, ferromagnetic implants and ferromagnetic foreign bodies, pregnancy. - Inability to tolerate MR imaging secondary to an inability to hold breath for a short time or have claustrophobia. - Non-compliant with visit instructions, including following procedure instructions - Severe allergy to animal dander or animal-instigated asthma - Specific to gadolinium-based contrast agents: Renal function test does not meet CSMC standard of care MRI contrast protocol requirements (GFR <45ml/min) or previous allergic reaction to gadolinium-based contrast agents.* - Volunteers who have had four or more prior previous gadolinium contrast scan

Study Design


Intervention

Device:
Cardiac MRI
MRI with/without administration of a contrast agent and beta-blocker based upon the stage of method development, if no contraindications are present.
Drug:
Contrast
The intravenous gadolinium based contrast agent to be used in this study is Gadavist (up to 0.2 mmol/kg).
Beta blocker
Based upon the focus of the study at the time of the scan, a beta- blocker (metoprolol), in pill form based upon blood pressure and heart rate, may be administered to some subjects to improve the heart's ability to relax and slow the heart rate. The slower heart rate may improve image quality and lessen motion artifact.

Locations

Country Name City State
United States Cedars-Sinai Medical Center Los Angeles California

Sponsors (1)

Lead Sponsor Collaborator
Cedars-Sinai Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Plaque to Myocardial Ratio (PMR). PMR is defined as the ratio between the maximal signal intensity from a vessel wall region and the average signal from an adjacent myocardial area. Such metric is used to classify hyper-intense plaques, also known as "hot spots", which has PMR over 1.0. Day 1
Secondary Stenosis level (patient group only) Stenosis level will be evaluated at the vascular segments with visible lumen narrowing in each patient. The extent of a stenosis will be measured and recorded as a percentage, ranging from 0% to 100%, with 100% representing a complete occlusion. Day 1
See also
  Status Clinical Trial Phase
Withdrawn NCT02265146 - ORACLE-NIRS: Lipid cORe Plaque Association With CLinical Events: a Near-InfraRed Spectroscopy Study
Completed NCT02335086 - DNA Damage & Repair Proteins In Patients With Atherosclerotic Coronary Artery Disease N/A
Completed NCT00811772 - Trial of Drug Eluting Stent Versus Bare Metal Stent to Treat Coronary Artery Stenosis N/A
Recruiting NCT03322332 - Adipokines of Epicardial Adipose Tissue and Atherosclerosis of Coronary Arteries N/A
Completed NCT02305953 - Cytokines and Vascular Inflammation in Psoriasis N/A
Completed NCT01642173 - Assessment of Coronary Plaque Composition Using Optical Coherence Tomography Phase 1
Completed NCT02316782 - Bifurcation Lesion Analysis and STenting / BLAST
Completed NCT00548613 - Combination Stem Cell (MESENDO) Therapy for Utilization and Rescue of Infarcted Myocardium Phase 1
Terminated NCT00243308 - Serp-1 for the Treatment of Acute Coronary Syndrome Phase 2
Recruiting NCT05105750 - A Comparative Study of Indobufen and Aspirin in Patients With Coronary Atherosclerosis Phase 4
Completed NCT01722214 - Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis Phase 4
Terminated NCT01030328 - AFRICA: Atorvastatin Plus Fenofibric Acid (TriLipix) in the Reduction of Intermediate Coronary Atherosclerosis Phase 3
Suspended NCT00790764 - Phase II Combination Stem Cell Therapy for the Treatment of Severe Coronary Ischemia(CI) Phase 2
Active, not recruiting NCT01061398 - CT-FIRST: Cardiac Computed Tomography Versus Stress Imaging For Initial Risk STratification N/A
Completed NCT00431977 - Validation Study of Coronary CT Angiography as a Screening Tool in Asymptomatic Diabetes N/A
Completed NCT00431717 - Coronary Computed Tomography Angiography and SPECT in Asymptomatic Diabetes N/A
Recruiting NCT00155350 - Treatment of Coronary Atherosclerosis by Insulin Sensitizers in Insulin-Resistant Patients Phase 4
Recruiting NCT05708547 - Role of Mitophagy in Myeloid Cells During Coronary Atherosclerosis.
Terminated NCT02440646 - Natural History of Coronary Atherosclerosis in Real-World Stable Chest Pain Patients Underwent Computed Tomography Angiography in Comparison With Invasive Multimodality Imaging
Terminated NCT01268319 - CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow N/A